Isomab presents landmark safety data at ESC 2026, clearing the path for next-generation therapies to promote blood vessel growth in coronary artery disease
First comprehensive systematic review provides insights into the long-term safety profile of angiogenic approaches in coronary artery disease (CAD) – treatments designed to grow new blood vessels Data shows no evidence of increased cancer or retinopathy, resolving long-standing safety questions that have limited progress across the field The data supports approaches such as Isomab’s ISM-001, […]
Isomab appoints Dr Philip Brainin as Chief Executive Officer
Nottingham, UK, 18 March 2026 – IsomAb Ltd, a UK-based biotechnology company, today announced the appointment of Dr Philip Brainin as Chief Executive Officer (CEO) and member of the Board of Directors. IsomAb is developing transformative isoform‑specific antibody therapeutics for atherosclerotic disease. Dr Brainin is tasked with taking lead candidate ISM-001 for chronic stable angina […]
Isomab makes two key appointments; Dr Shi Yin Foo as Non-Executive Director and Dr Gary Burgess as CMO
Dr Shi Yin Foo is the scientific founder and CEO of Arvada Therapeutics. She is a cardiologist and immunologist with over 20 years of experience as a practicing physician and a catalyst in advancing innovative new programs through various stages of drug development. She has been in executive roles at multiple biotechnology companies, including Novartis […]
Isomab Announces Strategic Collaboration with Catalent
Master Service Agreement for ISM-001 First work program initiated August 2024 Strategic collaboration encompassing initial process development through to clinical trial supply IsomAb Ltd, a UK-based biotechnology company developing developing isoform-specific, disease modifying antibody treatments for serious and life-threatening diseases, today announced it has entered into a strategic collaboration with Catalent, Inc.; the leader […]
Isomab Appoints Dr Anker Lundemose as a Non-Executive Director
NOTTINGHAM, UK – April 16th, 2024 IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, today announced the appointment of Dr Anker Lundemose to its Board of Directors, as an independent non-executive Director. This follows the recent closing of a £7.5 million Seed funding in late February. […]
Isomab Announces Close of £7.5 Million Financing to Accelerate Lead Candidate
NOTTINGHAM, UK – Feb 20th 2024 – IsomAb Ltd, a UK-based biotechnology company, announced today the closing of a £7.5 million (approximately US$9.4 million) Seed financing round, led by Broadview Ventures, with further backing from existing investor, SCVC and participation from MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures […]